Physician profile
Mark Warren Udy
NPI 1659405314
$9,254.13
in general payments reported to CMS, 2019-2025
30 companies · $1,394 in 2025
The $1,394 reported for 2025 was more than what 86% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,815 · 2022: $1,143 · 2023: $1,456 · 2024: $1,445 · 2025: $1,394.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,295.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,295.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $5,081.70 | 2021-2025 | Coveredge 32, Artisan, General - Pain Management |
| Abbvie INC. | $1,102.20 | 2022-2025 | |
| Pfizer INC. | $305.82 | 2023-2025 | |
| Nevro Corp. | $254.35 | 2021-2023 | Senza |
| Lundbeck LLC | $244.43 | 2021-2025 | Vyepti |
| Relievant Medsystems, INC. | $238.77 | 2021-2023 | Intracept |
| Medtronic, INC. | $210.98 | 2022-2024 | Intellis Adaptivestim, Venaseal, Kyphon Express II Kyphopak Tray |
| Teva Pharmaceuticals USA, INC. | $183.50 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $172.39 | 2021-2024 | Relistor |
| Abbott Laboratories | $170.20 | 2021-2022 | |
| Collegium Pharmaceutical, INC. | $154.68 | 2021-2024 | Belbuca, Xtampza |
| Nalu Medical, INC. | $149.63 | 2021-2023 | Nalu Neurostimulation System |
| Averitas Pharma INC. | $106.53 | 2023-2025 | Qutenza |
| Allergan, INC. | $106.33 | 2021 | |
| Redhill Biopharma INC. | $105.78 | 2021-2023 | Movantik, Aemcolo, Talicia |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Spr Therapeutics, INC | $103.48 | 2023-2025 | Sprint Pns System |
| Grt US Holding, INC. | $87.95 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $83.60 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $70.63 | 2021 | |
| Amgen INC. | $65.86 | 2021-2022 | |
| Vertos Medical, INC. | $59.32 | 2024 | Mild Device Kit |
| Mml US, INC. | $56.45 | 2025 | Reactiv8 |
| Bioventus LLC | $23.46 | 2022 | |
| Depuy Synthes Sales INC. | $19.01 | 2025 | Monovisc |
| Lilly USA, LLC | $18.27 | 2021 | |
| Radius Health, INC. | $17.84 | 2021 | |
| Si-Bone, INC. | $17.06 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $16.21 | 2025 | |
| Biodelivery Sciences International, INC. | $14.81 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $12.89 | 2023 | Seglentis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Udy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.